WSJ -- The FDA is summoning a panel of experts to consider whether drug makers should be forced to study the cardiovascular effects of diabetes drugs. It’s a complicated question that raises some thorny (and interesting) issues.
WSJ -- The FDA is summoning a panel of experts to consider whether drug makers should be forced to study the cardiovascular effects of diabetes drugs. It’s a complicated question that raises some thorny (and interesting) issues.
